

Supplementary Table 5. Factors associated with SGLT2i initiation among patients with type 2 diabetes mellitus and heart failure

Variable	SGLT2i treatment		Unadjusted OR (95% CI)	Adjusted OR (95% CI)
	Non-user	User		
Age (/10 years)			0.60 (0.60–0.61) ^c	0.57 (0.57–0.58) ^c
Sex				
Male	171,668 (87.4)	24,790 (12.6)	1 (reference)	1 (reference)
Female	159,468 (90.4)	16,927 (9.6)	0.74 (0.72–0.75) ^c	0.97 (0.95–0.99) ^b
Residents				
Urban	132,026 (88.3)	17,426 (11.7)	1 (reference)	1 (reference)
Rural	199,110 (89.1)	24,291 (10.9)	0.92 (0.91–0.94) ^c	0.93 (0.91–0.95) ^c
Household income				
High (75%)	229,444 (88.9)	28,759 (11.1)	1 (reference)	1 (reference)
Low (25%)	101,692 (88.7)	12,958 (11.3)	1.02 (0.99–1.04)	0.95 (0.93–0.98) ^c
Anti-diabetic drugs				
Metformin				
No	128,394 (93.7)	8,706 (6.4)	1 (reference)	1 (reference)
Yes	202,742 (86.0)	33,011 (14.0)	2.40 (2.34–2.46) ^c	1.97 (1.92–2.03) ^c
Sulfonylurea				
No	218,977 (90.4)	23,336 (9.6)	1 (reference)	1 (reference)
Yes	112,159 (85.9)	18,381 (14.1)	1.54 (1.51–1.57) ^c	1.49 (1.45–1.52) ^c
Insulin				
No	226,645 (87.3)	33,115 (12.8)	1 (reference)	1 (reference)
Yes	104,491 (92.4)	8,602 (7.6)	0.56 (0.55–0.58) ^c	0.73 (0.71–0.75) ^c
DPP-4i				
No	178,587 (88.9)	22,282 (11.1)	1 (reference)	1 (reference)
Yes	152,549 (88.7)	19,435 (11.3)	1.02 (1.00–1.04) ^a	0.75 (0.74–0.77) ^c
Comorbidities				
Hypertension				
No	55,219 (89.2)	6,709 (10.8)	1 (reference)	1 (reference)
Yes	275,917 (88.7)	35,008 (11.3)	1.04 (1.02–1.07) ^b	0.98 (0.94–1.02)
Dyslipidemia				
No	113,012 (94.4)	6,667 (5.6)	1 (reference)	1 (reference)
Yes	218,124 (86.2)	35,050 (13.8)	2.72 (2.65–2.80) ^c	1.59 (1.48–1.72) ^c
CV medications				
ACEi/ARB (yes)				
No	114,115 (90.7)	11,668 (9.3)	1 (reference)	1 (reference)
Yes	217,021 (87.8)	30,049 (12.2)	1.35 (1.32–1.39) ^c	1.30 (1.26–1.34) ^c
Beta-blocker (yes)				
No	222,043 (89.6)	25,810 (10.4)	1 (reference)	1 (reference)
Yes	109,093 (87.3)	15,907 (12.7)	1.25 (1.23–1.28) ^c	1.16 (1.14–1.19) ^c

Values are presented as number (%).

SGLT2i, sodium-glucose cotransporter 2 inhibitor; OR, odds ratio; CI, confidence interval; DPP-4i, dipeptidyl peptidase-4 inhibitor; CV, cardiovascular; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

^a*P*<0.05, ^b*P*<0.001, ^c*P*<0.0001.